Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | TBCRC 048: olaparib monotherapy in metastatic breast cancer

Nadine Tung • 27 May 2020
ASCO 2020
Breast Cancer Olaparib
TBCRC 048

Nadine Tung, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA, talks about the phase II study of olaparib monotherapy in patients with metastatic breast cancer with germline or somatic mutations in DNA damage response (DDR) pathway genes. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals